Andor Glaudemans
prof. dr.
I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists. Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
Diagnostic imaging of the diabetic foot: an EANM evidence-based guidance
Published in: European Journal of Nuclear Medicine and Molecular Imaging
Access to document
10.1007/s00259-024-06693-y
document
PURPOSE: Consensus on the choice of the most accurate imaging strategy in diabetic foot infective and non-infective complications is still lacking. This document provides evidence-based recommendations, aiming at defining which imaging modality should be preferred in different clinical settings. METHODS: This working group includes 8 nuclear medicine physicians appointed by the European Association of Nuclear Medicine (EANM), 3 radiologists and 3 clinicians (one diabetologist, one podiatrist and one infectious diseases specialist) selected for their expertise in diabetic foot. The latter members formulated some clinical questions that are not...
Chiara Lauri, Edel Noriega-Álvarez, Riddhika M Chakravartty, Olivier Gheysens, Andor W J M Glaudemans, Riemer H J A Slart, Thomas C Kwee, Frédéric Lecouvet, Emmanouil Panagiotidis, Jules Zhang-Yin, Jose Luis Lazaro Martinez, Benjamin A Lipsky, Luigi Uccioli, Alberto Signore
Prevalence of wild-type transthyretin amyloidosis in a prospective heart failure cohort with preserved and mildly reduced ejection fraction: Results of the Amylo-VIP-HF study
Published in: European Journal of Heart Failure
Access to document
10.1002/ejhf.3186
document
Alwin Tubben, Hendrea S.A. Tingen, Niek H.J. Prakken, Vanessa P.M. van Empel, Thomas M. Gorter, Laura M.G. Meems, Olivier C. Manintveld, Michiel Rienstra, Robert G. Tieleman, Andor W.J.M. Glaudemans, Dirk J. van Veldhuisen, Riemer H.J.A. Slart, Hans L.A. Nienhuis, Peter van der Meer
Correlation between Histopathological Prognostic Tumor Characteristics and [18F]FDG Uptake in Corresponding Metastases in Newly Diagnosed Metastatic Breast Cancer
Published in: Diagnostics
Access to document
10.3390/diagnostics14040416
document
BACKGROUND: In metastatic breast cancer (MBC), [ 18F]fluorodeoxyglucose positron emission tomography/computed tomography ([ 18F]FDG-PET/CT) can be used for staging. We evaluated the correlation between BC histopathological characteristics and [ 18F]FDG uptake in corresponding metastases. PATIENTS AND METHODS: Patients with non-rapidly progressive MBC of all subtypes prospectively underwent a baseline histological metastasis biopsy and [ 18F]FDG-PET. Biopsies were assessed for estrogen, progesterone, and human epidermal growth factor receptor 2 (ER, PR, HER2); Ki-67; and histological subtype. [ 18F]FDG uptake was expressed as maximum standardized uptake value (SUV max) and...
IMPACT-Metastatic Breast Consortium, Jorianne Boers, Bertha Eisses, Mieke C Zwager, Jasper J L van Geel, Frederike Bensch, Erik F J de Vries, Geke A P Hospers, Andor W J M Glaudemans, Adrienne H Brouwers, Martijn A M den Dekker, Sjoerd G Elias, Evelien J M Kuip, Carla M L van Herpen, Agnes Jager, Astrid A M van der Veldt, Daniela E Oprea-Lager, Elisabeth G E de Vries, Bert van der Vegt, Willemien C Menke-van der Houven van OordtCarolina P Schröder
Pharmacokinetic Analysis of [18F]FES PET in the Human Brain and Pituitary Gland.
Published in: Molecular Imaging and Biology
Access to document
10.1007/s11307-023-01880-z
document
PURPOSE: Estrogen receptors (ER) are implicated in psychiatric disorders. We assessed if ER availability in the human brain could be quantified using 16α-[ 18F]-fluoro-17β-estradiol ([ 18F]FES) positron emission tomography (PET). PROCEDURES: Seven post‑menopausal women underwent a dynamic [ 18F]FES PET scan with arterial blood sampling. A T1-weighted MRI was acquired for anatomical information. After one week, four subjects received a selective ER degrader (SERD), four hours before the PET scan. Pharmacokinetic analysis was performed using a metabolite-corrected plasma curve as the input function. The optimal kinetic model was...
Nafiseh Ghazanfari, Janine Doorduin, Chris W J van der Weijden, Antoon T M Willemsen, Andor W J M Glaudemans, Aren van Waarde, Rudi A J O Dierckx, Erik F J de Vries
At the cutting-edge: what’s the latest in imaging to diagnose Sjögren’s syndrome?
Published in: Expert review of clinical immunology
Access to document
10.1080/1744666X.2023.2283588